A Jamaican company has begun legally exporting proprietary pharmaceutical products with cannabis-derived THC, as well as hemp-derived CBD and other cannabinoids to the United States and Brazil.
The Jamaica Promotions Corporation (JAMPRO) says the company, Pure Jamaican through its pharma manufacturer Seven-10 Pharmaceuticals are elevating Jamaica’s role in the global cannabis supply chain.
The permissions to export pure Jamaican pharmaceutical products containing THC to the US were granted by Jamaica’s Ministry of Health and Wellness to Seven-10 Pharmaceuticals pursuant to valid corresponding import permits received from the US drug enforcement administration, DEA.
The products were shipped to a DEA licensed facility in the US for successful analytical testing.
Once the DEA approves the rescheduling of THC from schedule 1 to schedule 3 in the US, as is widely anticipated, Seven-10 intends to request DEA permits to ship its products to patients in the US, subject to valid doctor prescriptions and all relevant DEA, FDA and State Pharmacy Distribution Regulations.
Meanwhile, Seven-10 has begun shipping tinctures with THC and other cannabinoids directly to patients in Brazil, pursuant to anvisa import permits.
Together, Brazil and the US represent populations of more than 500 million people, providing tremendous potential demand.
JAMPRO’s President, Shullette Cox, says “the growth of the cannabis industry for medicinal purposes has been a priority of the Government and particularly, the export of value-added products from Jamaica.
…30..
